Recombinant Human S100P/S100E Protein (PKSH030800)
For research use only.
| Synonyms | MIG9, Protein S100-E, Protein S100-P, S100 Calcium-Binding Protein P, S100E, S100P |
| Species | Human |
| Expression Host | E.coli |
| Sequence | Met 1-Lys 95 |
| Accession | P25815 |
| Calculated Molecular Weight | 10.4 kDa |
| Tag | None |
| Bio-activity | Not validated for activity |
| Purity | > 97 % as determined by reducing SDS-PAGE. |
| Endotoxin | Please contact us for more information. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation |
Lyophilized from sterile PBS, pH 7.5 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
| Background | Protein S100-P; also known as Protein S100-E; S100 calcium-binding protein P; S100P and S100E; is a nucleus and cytoplasm protein which belongs to theS-100 family. S100P / S100E contains twoEF-hand domains. S100P protein regulates calcium signal transduction and mediates cytoskeletal interaction; protein phosphorylation and transcriptional control. S100P / S100E overexpression can upregulate androgen receptor expression and thereby promote prostate cancer progression by increasing cell growth. S100P / S100E may directly confer resistance to chemotherapy. S100P / S100E induction may be considered an important step in the initial stage of lung adenocarcinomas; whereas its downregulation in advanced stages seems to be important for tumour progression in which DNA methylation and/or feedback transcription processes play a critical role. S100P / S100E plays a major role in the aggressiveness of pancreatic cancer that is likely mediated by its ability to activate RAGE. Interference with S100P / S100E may provide a novel approach for treatment of pancreatic cancer. S100P / S100E could be considered a potential drug target or a chemosensitization target; and could also serve as a biomarker for aggressive; hormone-refractory and metastatic prostate cancer. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
